Agonist-directed signaling of serotonin 5-HT2c receptors: Differences between serotonin and lysergic acid diethylamide (LSD)

被引：7

作者：

Backstrom J.R. ^{[1
]}

Chang M.S. ^{[1
]}

Chu H. ^{[1
]}

Niswender C.M. ^{[1
]}

Sanders-Bush E. ^{[1
]}

机构：

[1] Department of Pharmacology, Center for Molecular Neuroscience, Vanderbilt University School of Medicine, 432 Medical Research Building I, Nashville, TN

来源：

Neuropsychopharmacology | 1999年 / 21卷 / Suppl 1期

关键词：

5-HT2A; 5-HT2C; Calcium; Hallucinogen; Phosphoinositide; Phosphorylation; Serotonin;

D O I：

10.1016/S0893-133X(99)00005-6

中图分类号：

学科分类号：

摘要：

For more than 40 years the hallucinogen lysergic acid diethylamide (LSD) has been known to modify serotonin neurotransmission. With the advent of molecular and cellular techniques, we are beginning to understand the complexity of LSD‘s actions at the serotonin 5-HT2 family of receptors. Here, we discuss evidence that signaling of LSD at 5-HT2C receptors differs from the endogenous agonist serotonin. In addition, RNA editing of the 5-HT2Creceptor dramatically alters the ability of LSD to stimulate phosphatidylinositol signaling. These findings provide a unique opportunity to understand the mechanism(s) of partial agonism. © 1999 American College of Neuropsychopharmacology.

引用

页码：77S / 81S

页数：4

共 25 条

[1]

Backstrom, J.R., Westphal, R.S., Canton, H., Sanders-Bush, E., Identification of rat serotonin 5-HT2C receptors as glycoproteins containing N-Linked oligosaccharides (1995) Mol Brain Res, 33, pp. 311-318

[2]

Backstrom, J.R., Sanders-Bush, E., Generation of antipeptide antibodies against serotonin 5-HT2A and 5-HT2C receptors (1997) J Neurosci Methods, 77, pp. 109-117

[3]

Barker, E.L., Westphal, R.S., Schmidt, D., Sanders-Bush, E., Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor lignads (1994) J Biol Chem, 269, pp. 11687-11690

[4]

Berg, K.A., Maayani, S., Clarke WP (1996): 5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like function via arachadonic acid metabolism Mol Pharma- Col, 50, pp. 1017-1023

[5]

Berg, K.A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., Clarke, W.P., Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus (1998) Mol Pharmacol, 54, pp. 94-104

[6]

Burns, C.M., Chu, H., Rueter, S.M., Hutchinson, L.K., Canton, H., Sanders-Bush, E., Emeson, R.B., Regulation of sero- tonin-2C receptor G-protein coupling by RNA editing (1997) Nature, 387, pp. 303-308

[7]

Burris, K.D., Breeding, M., Sanders-Bush E (1991): (+)Lysergic acid diethylamide, but not its nonhallucinogenic conge- ners, is a potent serotonin 5-HT1C receptor agonist J Pharmacol Exp Ther, 258, pp. 891-896

[8]

Egan, C.T., Herrick-Davis, K., Miller, K., Glennon, R.A., Teitler, M., Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors (1998) Psychopharmacology, 136, pp. 409-414

[9]

Gaddum, J.H., Antagonism between lysergic acid dieth- ylamide and 5-hydroxytryptamine (1953) J Physiol (London), 121, p. 15

[10]

Grotewiel, M.S., Chu, H., Sanders-Bush E (1994): M-chlorophe- nylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts J Pharmacol Exp Ther, 271, pp. 1122-1126

← 1 2 3 →